Contents

Search


maralixibat; lopixibat (Livmarli)

Indications: - treatment of cholestatic pruritus in patients with Alagille syndrome >= 1 year Dosage: - 380 ug/kg once daily, taken 30 minutes before 1st meal of day - starting dose: 190 ug/kg orally once daily - increase to 380 ug/kg once daily after one week, as tolerated Oral solution: 9.5 mg of maralixibat per mL. Adverse effects: - most common (> 5%) - diarrhea, abdominal pain, vomiting, fat-soluble vitamin deficiency, liver function test abnormalities, gastrointestinal bleeding, bone fractures Laboratory: - baseline & periodic liver function tests Mechanism of action: - ileal bile acid transporter (IBAT) inhibitor

General

enzyme inhibitor gastrointestinal agent

Database Correlations

PUBCHEM correlations

References

  1. Medscape: maralixibat (Rx) https://reference.medscape.com/drug/livmarli-maralixibat-4000208
  2. Highlights of preascribing information maralixibat (Livmarli) https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214662s000lbl.pdf